Michigan-led research presents a new way of uncovering predictive biomarkers when data from large randomized trials aren’t available.
Ian Demsky is a senior writer and public relations representative for the University of Michigan Rogel Cancer Center. Ian joined the cancer center communications team in 2019. Prior to that he served as director of communications for the U-M Life Sciences Institute and science editor for Medicine at Michigan Magazine.
A 600-patient randomized clinical trial supports pembrolizumab and chemotherapy as a first-line treatment
A new study finds that U-M-designed compounds led to significantly smaller, slower-growing tumors.
A new approach to RNA sequencing reveals thousands of previously inaccessible RNA fragments in blood plasma that might serve as disease- and organ-specific biomarkers.
Researchers have shown how tumor-associated macrophages release compounds that block gemcitabine in the most common type of pancreatic cancer
To Predict Which Cancer Cells Will Attack the Brain, Scientists Harness the Power of Artificial Intelligence
A new precision medicine approach developed at the University of Michigan aims to predict cancer’s likelihood of migrating to the brain, and to aid in the search for new treatments